



Press Release

Hyloris Pharmaceuticals Notice of Half Year 2020 Results and Conference Call

Liège (Belgium), 30 July 2020, 9am CEST – Hyloris Pharmaceuticals SA, an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, announces today that it will publish its consolidated results for the half year 2020 on **Thursday, 6 August 2020 at 9am CEST**.

In addition to the press release, Stijn Van Rompay, Chief Executive Officer will host a conference call, conducted in English, to present the results, followed by a live Q&A session.

This conference call will be held on **Thursday, 6 August 2020 at 2pm CEST / 1pm BST / 8am EDT** and can be accessed using the dial-in details below:

Event Plus Passcode:	2533728
Belgium, Brussels	02 793 3847
Belgium	08 004 8471
United States, New York	16 467 413 167
United States	18 778 709 135
United Kingdom	08 444 819 752
France	08 0510 1465
Netherlands	08 000 235 015

-Ends-

For more information, please contact:

Hyloris Pharmaceuticals

Stijn Van Rompay, CEO

+32 (0)4 346 02 07

contact@hyloris.com

Consilium Strategic Communications

Amber Fennell, Chris Welsh, Lucy Featherstone

+44 20 3709 5700

hyloris@consilium-comms.com

Note to Editors

About Hyloris Pharmaceuticals SA

Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris' portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company's partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company's wider portfolio. Read more at www.hyloris.com. Hyloris stands for "high yield, lower risk" and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.